| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1031171874 |
| P356 | DOI | 10.1023/A:1016476024293 |
| P698 | PubMed publication ID | 12184521 |
| P2093 | author name string | David Bass | |
| Stephen D H Malnick | |||
| Nadia Sokolowski | |||
| Stuart Becker | |||
| Marcus Schumann | |||
| Raia Gratz | |||
| P2860 | cites work | Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice | Q73838431 |
| Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial | Q77374966 | ||
| Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference | Q77626838 | ||
| Biologic therapy for inflammatory bowel disease | Q85829129 | ||
| Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses | Q24562026 | ||
| Interleukin-10-deficient mice develop chronic enterocolitis | Q29547881 | ||
| The relationship between infliximab treatment and lymphoma in Crohn's disease | Q30304487 | ||
| Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12- and gamma interferon-dependent mechanism | Q33767365 | ||
| Anti-inflammatory cytokines | Q33892589 | ||
| Increased concentrations of interleukin 1 beta, interleukin-2, and soluble interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inflammatory bowel disease | Q34375240 | ||
| Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease | Q34394083 | ||
| Tumour necrosis factor (TNF) binding proteins (soluble TNF receptor forms) with possible roles in inflammation and malignancy | Q40770719 | ||
| Does administration of infliximab increase susceptibility to listeriosis? | Q45111702 | ||
| Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. | Q53540951 | ||
| A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. | Q53964227 | ||
| Lactobacillus species prevents colitis in interleukin 10 gene–deficient mice | Q59120727 | ||
| Tumour necrosis factor alpha in stool as a marker of intestinal inflammation | Q67512879 | ||
| Enhanced mucosal cytokine production in inflammatory bowel disease | Q67531214 | ||
| Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis | Q68612934 | ||
| Epidemiology of inflammatory bowel disease | Q68908577 | ||
| Experimental models of inflammatory bowel disease | Q71737271 | ||
| Antibodies to tumour necrosis factor alpha as treatment for Crohn's disease | Q73639475 | ||
| P433 | issue | 8 | |
| P921 | main subject | inflammatory bowel diseases | Q917447 |
| P304 | page(s) | 1723-1727 | |
| P577 | publication date | 2002-08-01 | |
| P1433 | published in | Digestive Diseases and Sciences | Q15716711 |
| P1476 | title | Murine monoclonal anti-tNF antibody administration has a beneficial effect on inflammatory bowel disease that develops in IL-10 knockout mice | |
| P478 | volume | 47 |
| Q80600314 | Animal models of inflammatory bowel disease |
| Q39453169 | Anti-TNFα alters the natural history of experimental Crohn's disease in rats when begun early, but not late, in disease |
| Q34357992 | Downregulation of the NHE3-binding PDZ-adaptor protein PDZK1 expression during cytokine-induced inflammation in interleukin-10-deficient mice |
| Q29615500 | Inflammatory bowel disease |
| Q39793093 | Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis |
| Q33795727 | Probiotic Lactobacillus spp. diminish Helicobacter hepaticus-induced inflammatory bowel disease in interleukin-10-deficient mice |
Search more.